{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:38:26Z","timestamp":1772120306418,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.amjopharm.2009.11.005","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T05:11:53Z","timestamp":1264482713000},"page":"343-354","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of irinotecan-based chemotherapy regimens in elderly medicare patients with metastatic colorectal cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Nour A.","family":"Obeidat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise G.","family":"Pradel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilene H.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"DeLisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Daniel","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2009.11.005_bib1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2165\/00003495-200767130-00004","article-title":"Metastatic colorectal cancer: Current systemic treatment options","volume":"67","author":"Board","year":"2007","journal-title":"Drugs."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial [published correction appears in Lancet. 2000;355:1372]","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1377\/hlthaff.28.1.148","article-title":"Medicare's future: Cancer care","volume":"28","author":"Etheredge","year":"2009","journal-title":"Health Aff (Millwood)."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10552-006-0072-0","article-title":"Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000\u20132020","volume":"17","author":"Mariotto","year":"2006","journal-title":"Cancer Causes Control."},{"issue":"Suppl 8","key":"10.1016\/j.amjopharm.2009.11.005_bib11","first-page":"IV-3","article-title":"Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.23244","article-title":"Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population","volume":"112","author":"Dobie","year":"2008","journal-title":"Cancer."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jnci\/djj159","article-title":"Completion of therapy by Medicare patients with stage III colon cancer","volume":"98","author":"Dobie","year":"2006","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2003.06.178","article-title":"Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort","volume":"21","author":"Ayanian","year":"2003","journal-title":"J Clin Oncol."},{"issue":"Suppl 8","key":"10.1016\/j.amjopharm.2009.11.005_bib16","first-page":"IV-55","article-title":"Utility of the SEER-Medicare data to identify chemotherapy use","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib17","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.2001.19.17.3712","article-title":"Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results\u2014Medicare","volume":"19","author":"Schrag","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00005650-200004000-00008","article-title":"Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment","volume":"38","author":"Cooper","year":"2000","journal-title":"Med Care."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.23228","article-title":"Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002?","volume":"112","author":"Gross","year":"2008","journal-title":"Cancer."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib20","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1200\/JCO.2004.10.218","article-title":"Use of surgery among elderly patients with stage IV colorectal cancer","volume":"22","author":"Temple","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1245\/ASO.2005.06.012","article-title":"Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000","volume":"12","author":"Cook","year":"2005","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cncr.22448","article-title":"Survival after hepatic resection in metastatic colorectal cancer: A populationbased study","volume":"109","author":"Cummings","year":"2007","journal-title":"Cancer."},{"issue":"Suppl 8","key":"10.1016\/j.amjopharm.2009.11.005_bib24","first-page":"IV-43","article-title":"Use of SEER-Medicare data for measuring cancer surgery","volume":"40","author":"Cooper","year":"2002","journal-title":"Med Care."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1524-4733.2002.51083.x","article-title":"The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer","volume":"5","author":"Delea","year":"2002","journal-title":"Value Health."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cncr.21271","article-title":"Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity","volume":"104","author":"Du","year":"2005","journal-title":"Cancer."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib28_1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib28_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/0895-4356(93)90104-9","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/01.mlr.0000223475.70440.07","article-title":"In search of the perfect comorbidity measure for use with administrative claims data: Does it exist?","volume":"44","author":"Baldwin","year":"2006","journal-title":"Med Care."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"issue":"Suppl 8","key":"10.1016\/j.amjopharm.2009.11.005_bib32","doi-asserted-by":"crossref","first-page":"IV","DOI":"10.1097\/00005650-200208001-00003","article-title":"Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations","volume":"40","author":"Bach","year":"2002","journal-title":"Med Care."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib33","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1002\/cncr.22316","article-title":"Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer","volume":"107","author":"Hershman","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib34","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1200\/JCO.2006.05.7844","article-title":"Radiation therapy after mastectomy between 1991 and 1999 in elderly women: Response to clinical trial information","volume":"24","author":"Punglia","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model [published correction appears in ComputMethods Programs Biomed. 2008;89:313\u2013314]","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib36","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.amjopharm.2009.11.005_bib37","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1158\/1078-0432.CCR-07-1472","article-title":"Irinotecan pharmacogenetics: Influence of pharmacodynamic genes","volume":"14","author":"Hoskins","year":"2008","journal-title":"Clin Cancer Res."}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154359460900083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154359460900083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T13:58:26Z","timestamp":1544709506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154359460900083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S154359460900083X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2009.11.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1649963.1152061","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1649963.1790054","asserted-by":"object"}]},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}